Non-Insured Health Benefits Newsletter
First Canadian Health
News and Information for Our NIHB Providers
NIHB Toll-Free Inquiry Centre: 1-888-511-4666
For our Pharmacy Providers
Spring 2002
News and Views
Welcome to the spring 2002 edition of our NIHB quarterly newsletter.
We are now into our fourth year of operations as the claims processor
for the NIHB Program of the First Nations and Inuit Health Branch
(FNIHB) of Health Canada.
Again, we would like to thank you for your support as you continue
to provide quality health services to First Nations and Inuit clients
of the NIHB Program.
As always, your comments and questions are welcome. Please contact
the FCH NIHB Toll-Free Inquiry Centre at 1-888-511-4666, or send
your correspondence to:
FCH Provider Relations
3080 Yonge Street, Suite 3002
Toronto ON M4N 3N1
Spring 2002 NIHB Drug Benefit List (DBL) Update
Please find attached the spring 2002 updates to the NIHB Drug
Benefit List (DBL). The changes announced in the updates are reflected
in the April 1, 2002 NIHB DBL.
Providers who requested a hard copy of the NIHB DBL will be receiving
it shortly.
For those who wish a hard copy, your request must be submitted
using the form found in the winter 2001-2002 NIHB Pharmacy Newsletter
no later than June 1, 2002. After that time hard copies will not
be provided.
The revised NIHB DBL as well as the updates can be downloaded
online at the Internet address:
http://www.hc-sc.gc.ca/fnihb/nihb/pharmacy/drugbenefitlist/index.htm
Should you have any questions, please contact the First Canadian
Health (FCH) NIHB Toll-Free Inquiry Centre at 1-888-511-4666.
New Time Limit Calculation for Smoking Cessation Therapy
Nicotine patches, Nicotine gum (Nicorette®) and Bupropion
tablets (Zyban®)
The following quantities are the maximum amounts of either product
that can be issued over a one-year period:
Nicotine Patches:
Habitrol 84 patches; or
Nicoderm 70 patches; or
Nicotrol 70 patches
Gum (Nicorette®):
945 pieces
Bupropion tablets (Zyban®):
180 tablets
(Quantities are based on a 3-month treatment)
Once the maximum quantity has been reached, the client will be
eligible again for coverage for Smoking Cessation Therapy 12 months
from the day the initial prescription was filled.
Pharmacy Claim Form - Date Format
Please note that dates to be used on paper claim form
submissions must always follow this format: DD/ MM/ CCYY.
Failure to use the format indicated may result in claim
rejection since the submitted date will not match the date on
the system (e. g. in the case of dates of birth).
Emergency Supply
When a drug requiring prior approval is needed on an emergency
basis, and timely access to the NIHB Drug Exception Centre is not
possible (e.g. statutory holidays and after hours), a pharmacist
may dispense an initial course of treatment (maximum of
four days). It is important that the pharmacist contact
the NIHB Drug Exception Centre as soon as possible for an approval
to be backdated to cover the emergency supplies. Additional dispensing
of the drug must follow the usual prior approval process.
Once a decision is made on a prior approval request, it is communicated
to the pharmacist by fax. If a prior approval is granted, the pharmacist
is provided with a Prior Approval number and the details of the
approved benefit (description, maximum value, frequency or time
limitation, etc). The Prior Approval number must be included on
any subsequent claim submitted for the approved drug benefit.
FCH Provider Number
Providers are reminded to indicate their FCH Provider Number (usually
a 10-digit number starting with 5 leading zeros, with the exception
of Quebec and some pharmacies in British Columbia) and full pharmacy
provider name on all paper claims submitted for processing.
Failure to do so will result in the claim being returned for completion.
MS&E Prior Approval Confirmation Letters
Pharmacies selling medical supplies and/ or medical equipment
will shortly notice a change to the prior approval confirmation
letter mailing process. Individual confirmation letters issued
on the same day will be remitted to you in one envelope, rather
than in separate envelopes.
Documentation for Overriding Rejected Claims
Drug Utilization Review (DUR) information (or Drug Use Analysis
(DUA) in Quebec) is conveyed in the form of warning and information
messages depending on the severity of the potential problem. Currently,
claims to the NIHB Program prompting the following DUR (DUA) messages
will be rejected:
Duplicate Drug (MW)
Duplicate Drug Multi Pharmacy (MY)
Drug/ Drug Interaction Potential (ME)
Following appropriate review and evaluation by the pharmacist,
the rejected claim can be resubmitted along with a valid CPhA intervention
code.
In the Fall 2001 Newsletter, the NIHB Program outlined the requirement
that providers must complete and retain the appropriate documentation
of the nature of the intervention. This is documented either directly
on the prescription or on any hard copy or electronic version of
the patient profile. The Newsletter article indicated that the
information was to be available for consultation, if required,
during the claims verification/ auditing process.
As a result of conducting a number of on-site audits, the lack
of appropriate documentation of the nature of the intervention
has been identified as a significant problem. The NIHB Program
reaffirms that for all claims submitted after September 30, 2001
and reviewed as part of the claims verification/auditing process,
which are not supported by adequate documentation of the nature
of the DUR (DUA) intervention as defined above, are subject to
reclaim.
Attached are replacement pages for your NIHB Pharmacy/ MS & E
Provider Information Kit (PPIK). Please remove the existing pages
and insert the revised ones.
Published quarterly by First Canadian Health
Management Corporation Inc. at 3080 Yonge Street, Suite 3002, Toronto
ON M4N 3N1
|